Company / R&D Expense
Orthofix Medical Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$80.2M
FY2025
5-year range
$34.6M / $80.2M
FY2021-FY2025
Trend
+63.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $50M to $80M over the past 2 years.
Based on SEC 10-K filings.
$80M in FY2025 with a 5-year CAGR of +19.3%.
Improved from $50M to $80M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +27.1%
- 5-Year CAGR
- +19.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +19.3%, indicating consistent growth.
- In FY2025, r&d expense increased 63.5% year-over-year.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.2M | +63.5% |
| FY2024 | $49.1M | -1.1% |
| FY2023 | $49.6M | +27.1% |
| FY2022 | $39.1M | +12.8% |
| FY2021 | $34.6M | +4.3% |
| FY2020 | $33.2M | +11.8% |
| FY2019 | $29.7M | +3.1% |
| FY2018 | $28.8M | +9.1% |
| FY2017 | $26.4M | +5.6% |
| FY2016 | $25.0M | -6.6% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 28, 2026